

MICRO REPORT

Open Access



# Disrupting USP5/Cav3.2 interactions protects female mice from mechanical hypersensitivity during peripheral inflammation

Vinicius M. Gadotti and Gerald W. Zamponi\*

## Abstract

Cav3.2 T-type calcium channels are important for the signaling of nociceptive information in the primary afferent pain pathway. During neuropathy and peripheral inflammation, Cav3.2 channels are upregulated due to an increased association with the deubiquitinase USP5. Disrupting these interactions in male mice by the use of cell permeant peptides reverses mechanical and thermal hypersensitivity. Here we explore the effects of interfering with USP5 binding to the channel in female mice with synchronized estrous cycle. We show that intrathecal delivery of a cell-penetrating TAT peptide corresponding to the UBPC domain of USP5 fully reverses mechanical hypersensitivity in mice intraplantarly injected with Complete Freund's Adjuvant. Hence, the USP5 mediated dysregulation of Cav3.2 channel activity does not exhibit sex differences, and potential therapeutics targeting this interaction should be effective in both male and female subjects.

**Keywords:** T-type calcium channel, Ubiquitination, Inflammation, Pain, Sex differences, USP5

Cav3.2 T-type calcium channels are important for the propagation and transmission of nociceptive information in the afferent pain pathway [1]. Cav3.2 channel activity is aberrantly upregulated in a number of painful conditions, including visceral inflammation [2], diabetic neuropathy [3] and following nerve injury [4] whereas inhibition of T-type channel activity mediates analgesia [5, 6]. We reported that this enhancement of Cav3.2 channel activity in dorsal root ganglion neurons and spinal cord arises at least in part from an aberrant upregulation of USP5, a deubiquitinating enzyme that binds to the domain III-IV linker region of the Cav3.2  $\alpha 1$  subunit and deubiquitinates the channel [5]. As a result, this channel is protected from degradation, leading to an accumulation of channels in the plasma membrane and consequently larger whole cell currents. This upregulation of USP5 is observed after intraplantar injection of CFA, following peripheral nerve injury, during visceral

inflammation, in diabetic mice, and in a model of post-surgical pain [5, 7, 8]. Intrathecal delivery of cell permeant peptides corresponding to either the USP5 interaction site on the channel, or to the Cav3.2 binding site on USP5 reverses mechanical and thermal hypersensitivity associated with these conditions [5, 8, 9]. The studies described above were performed exclusively in male mice. Because there is evidence that certain aspects of pain signaling in the spinal cord exhibit marked sex differences [10, 11], it is important to determine whether disrupting USP5 interactions with Cav3.2 is equally protective in female mice.

To address this issue, we tested the analgesic effects of a Tat-cUBP1-USP5 peptide in female mice. This peptide corresponds to the Cav3.2 interaction site on USP5 and was previously shown by us to be effective in alleviating both mechanical hypersensitivity in CFA injected or nerve-injured male mice [9]. All animal experiments were approved by the Animal care committee of the University of Calgary. Female C57BL/6 J mice were purchased from Jackson laboratories. Their estrous cycle was synchronized and only mice under the proestrus

\* Correspondence: [zamponi@ucalgary.ca](mailto:zamponi@ucalgary.ca)

Department of Physiology and Pharmacology, Hotchkiss Brain Institute and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada




phase were tested. Mice received 20  $\mu$ l of CFA by intraplantar injection (i.pl.) 2 days prior to behavioral assessment. On the testing day, they were placed individually in plexiglass chambers on top of a grid floor and allowed to habituate for at least 90 min before testing. The Tat-cUBP1-USP5 peptide (10  $\mu$ g) or vehicle (10  $\mu$ l) were delivered via intrathecal injections according to methods described previously [12], at a dose that we had previously found effective in male mice [5]. Mice were then tested for mechanical hyperalgesia by assessing mechanical withdrawal threshold via a Dynamic Plantar Aesthesiometer (Ugo Basile, Varese, Italy). Data were then analyzed statistically using two-way analysis of variance.

Figure 1 shows the result of this experiment. Following CFA injection, mechanical withdrawal threshold decreased significantly compared to animals that had received a PBS injection into the hindpaw. Within 15 min of delivery of the Tat-cUBP1-USP5 peptide, there was a near complete reversal of mechanical hypersensitivity that declined over time, but remained statistically different from that observed following intrathecal delivery of vehicle. As in our previous studies with male mice, no behavioral abnormalities were observed following Tat-cUBP1-USP5 treatment. These data indicate that disrupting USP5/Cav3.2 interactions mediate analgesia irrespective of the sex of the animals, and by inference, that the USP5/Cav3.2 pathway is dysregulated in a non-sexually dimorphic way in mice following peripheral inflammation.

Closer inspection of the data, however, reveals some differences between male and female mice. First, at the same dose as the one examined here, the maximal effect of the Tat-cUBP1-USP5 peptide in the CFA model was lower in male mice compared to female mice, with males showing a maximal effect of 70–75% reversal of mechanical hypersensitivity. In this context it is noteworthy, however, that full reversal was observed with this dose in a nerve injury model [9]. Second, the kinetics of the action of the tat peptide were different between males and females, such that analgesia peaked after 45 min and declined more slowly in males compared to what we report here. The cellular and molecular basis of these differences is unclear at this point.

Chronic pain is a debilitating condition that is often refractory to treatment, and new avenues for therapeutic intervention are sorely needed. T-type calcium channels have been pursued as a potential pharmacological target for some time. Direct inhibitors of these channels are efficacious in various preclinical pain models, however, there has not been a successful human clinical phase II trial for T-type channel inhibitors [6]. Targeting dysregulation of ion channels is an attractive alternative approach to inhibiting ion flux through the channels, as such an approach that selectively targets channels that are being dysregulated while sparing their normal physiological function is an attractive alternative [13]. This may involve the disruption of protein-protein interactions as such as the one described here, and can



potentially be accomplished with small organic molecules rather than cell permeant peptides. Indeed, we have reported that small organic molecules identified in a compound library screen against the USP5/Cav3.2 interaction can show efficacy in various preclinical pain models [7]. The observation that disrupting the regulation of Cav3.2 by USP5 mediates analgesia in both female and male mice further underscores the utility of targeting Cav3.2 channel dysregulation in chronic pain as a possible therapeutic approach.

## Additional file

**Additional file 1:** Extended Methodology. (DOCX 24 kb)

## Abbreviations

CFA: Complete Freund's adjuvant; PBS: Phosphate buffer solution; USP5: Ubiquitin specific peptidase 5

## Acknowledgements

We thank Dr. Agustin Garcia-Caballero for providing the Tat-cUBP1-USP5 peptide.

## Funding

This work was supported by a Foundation Grant for the Canadian Institutes of Health Research and a Grant from Alberta Innovates. VMG is supported by the Vi Riddell program in Pediatric Pain. GWZ is a Canada Research Chair.

## Availability of data and materials

All data generated or analysed during this study are included in this published article (and its Additional file 1).

## Authors' contributions

VG and GWZ conceived the study and wrote the manuscript, VF performed experiments and analyzed the data, GWZ supervised the study. Both authors read and approved the final manuscript.

## Ethics approval and consent to participate

This study was approved by the University of Calgary's animal care committee.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 17 September 2018 Accepted: 11 October 2018

Published online: 19 October 2018

## References

- Bourinet E, Alloui A, Monteil A, Barrère C, Couette B, Poirot O, Pages A, et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. *EMBO J*. 2005;24(2):315–24.
- Marger F, Gelot A, Alloui A, Matricon J, Ferrer JF, Barrère C, Pizzoccaro A, et al. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. *Proc Natl Acad Sci U S A*. 2011;108(27):11268–73.
- Jagodic MM, Pathirathna S, Nelson MT, Mancuso S, Joksovic PM, Rosenberg ER, Bayliss DA, et al. Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. *J Neurosci*. 2007;27(12):3305–16.
- Jagodic MM, Pathirathna S, Joksovic PM, Lee W, Nelson MT, Naik AK, Su P, et al. Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. *J Neurophysiol*. 2008;99(6):3151–6.
- García-Caballero A, Gadotti VM, Stenkowski P, Weiss N, Souza IA, Hodgkinson V, Bladen C, et al. The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity. *Neuron*. 2014;83(5):1144–58.
- Snutch TP, Zamponi GW. Recent advances in the development of T-type calcium channel blockers for pain intervention. *Br J Pharmacol*. 2018;175(12):2375–83.
- Gadotti VM, Caballero AG, Berger ND, Gladding CM, Chen L, Pfeifer TA, Zamponi GW. Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain. *Mol Pain*. 2015;11:12. <https://doi.org/10.1186/s12990-015-0011-8>.
- Joksimovic SL, Joksimovic SM, Tesic V, García-Caballero A, Feseha S, Zamponi GW, Jevtovic-Todorovic V, et al. Selective inhibition of Cav3.2 channels reverses hyperexcitability of peripheral nociceptors and alleviates postsurgical pain. *Sci Signal*. 2018;11:545.
- García-Caballero A, Gadotti VM, Chen L, Zamponi GW. A cell-permeant peptide corresponding to the cUBP domain of USP5 reverses inflammatory and neuropathic pain. *Mol Pain*. 2016;12.
- Sorge RE, Mapplebeck JC, Rosen S, Beggs S, Taves S, Alexander JK, Martin LJ, et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. *Nat Neurosci*. 2015;18(8):1081–3.
- Mapplebeck JCS, Dalgarno R, Tu Y, Moriarty O, Beggs S, Kwok CHT, Halievski K, et al. Microglial P2X4R-evoked pain hypersensitivity is sexually dimorphic in rats. *Pain*. 2018;159(9):1752–63.
- Hyliden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. *Eur J Pharmacol*. 1980;67(2–3):313–6.
- Feldman P, Khanna R. Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides. *Neurosci Lett*. 2013;557:27–36.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

